Evidence map›Paper›PMID 40270827›Full record

ArticleFrontiers in microbiology2025

Gut microbiome signature in response to neoadjuvant chemoradiotherapy in patients with rectal cancer.

Tingmei Duan, Zhengting Ren, Haili Jiang, Yan Ding, Hongyan Wang, Fan Wang

Abstract read
In one paragraph

Article in Frontiers in microbiology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Tingmei DuanDepartment of Radiation Oncology, First Affiliated Hospital of Anhui Medical University, Hefei, China.
Zhengting RenDepartment of Radiation Oncology, First Affiliated Hospital of Anhui Medical University, Hefei, China.
Haili JiangDepartment of Integrated Chinese and Western Medicine Oncology, First Affiliated Hospital of Anhui Medical University, Hefei, China.
Yan DingDepartment of Radiation Oncology, First Affiliated Hospital of Anhui Medical University, Hefei, China.
Hongyan WangDepartment of Radiation Oncology, First Affiliated Hospital of Anhui Medical University, Hefei, China.
Fan WangDepartment of Radiation Oncology, First Affiliated Hospital of Anhui Medical University, Hefei, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Rectal cancer remains a leading cause of cancer-associated mortality, especially in advanced cases with limited treatment options. Emerging evidence suggests that the gut microbiome may influence the therapeutic efficacy of neoadjuvant chemoradiotherapy (CRT). Objective: This study aimed to explore the dynamic changes in gut microbiome composition and metabolic pathways in rectal cancer patients undergoing CRT. Methods: Paired fecal samples were collected from rectal cancer patients pre- and post-CRT. 16S rRNA amplicon sequencing and proteomics analysis were conducted to investigate microbial and metabolic alterations. Results: Significant shifts in the microbiome were observed, with Conclusion: These findings identify potential microbial biomarkers and metabolic pathways associated with CRT response, offering insights into personalized treatment strategies.

Indexed as

16S rRNA sequencinggut microbiomeneoadjuvant chemoradiotherapy (CRT)proteomicsrectal cancer

Identifiers

PMID40270827
PMCPMC12014591

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.